阿里皮普拉对抗抑郁药引起的不安腿综合征具有潜在的有效性:一系列病例
Yasuhito Nagai1,2, Koichi Miyakawa1,2
1Department of Psychiatry, Juntendo University Graduate School of Medicine, Tokyo, Japan.
概括
低剂量的阿里皮普拉有效治疗抗抑郁药引起的不安腿综合征 (RLS). 这项研究强调了aripiprazole的作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 抗抑郁药物可以诱导不安腿综合征 (RLS).
- 区分抗抑郁药诱导的RLS与阿卡西西亚对于正确的诊断和治疗至关重要.
- 国际不安腿综合征严重性评级尺度是评估RLS严重性的验证工具.
研究的目的:
- 调查阿里皮普拉在治疗抗抑郁药诱导的不安腿综合征 (RLS) 的疗效.
- 报告与抗抑郁药使用相关的RLS临床病例.
- 在抗抑郁药物治疗的背景下,区分RLS症状与阿卡西西亚.
主要方法:
- 一系列病例报告了三名与抗抑郁药使用相关的RLS患者.
- 基于症状特征 (日间变化,聚焦感觉) 的临床评估,区分RLS与阿卡西西亚.
- 使用国际不安腿综合征严重性评级尺度对RLS严重性的评估.
主要成果:
- 所有报告的病例都显示在抗抑郁药治疗期间症状恶化.
- 一个病例出现症状恶化,可能与阿里皮普拉停药有关.
- 在报告的病例中,阿里皮普拉治疗对RLS症状产生了积极影响.
结论:
- 阿里皮普拉在缓解抗抑郁药使用后的不安腿综合征 (RLS) 上是有效的.
- 较低剂量的阿里皮普拉可能足以控制抗抑郁药引起的RSL.
- 需要进一步的研究来证实aripiprazole在二次RLS中的疗效和最佳剂量.
相关概念视频
01:27Restless Leg Syndrome and Night Terrors
476
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
476
01:15REM Sleep Behavior Disorder
1.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
1.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
01:20Antiepileptic Drugs: Potassium Channel Activators
631
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
631
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880